RxDoctor Payments Data

Lorraine Dowdy, DO

Infectious Disease · South Miami, FLNPI 1760445944

Payments from drug & device makers

$26,597in general payments, 2019–2025

Across 561 payments — averaging $47.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$20K
  • Gilead$2K
  • Merck$1K
  • Insmed, Inc.$934
  • Paratek Pharmaceuticals, Inc.$636
  • Johnson & Johnson$503
  • plus $2K from 10 others
$703in research payments, 2019–2025

Across 6 payments — averaging $117.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Viiv Healthcare Company$703

What the payments were for

  • Consulting fees$11,37044%
  • Travel & lodging$1,1464%
  • Food & beverage$12,74550%
  • Education$3831%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,597 in reported general payments places this provider in the 85th percentile of 669 infectious disease providers in Florida.

See all infectious disease providers in Florida

Medicare billing

Part B allowed, 2024
$40,910
Medicare patients
60
Services billed
1,181

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala88$358,991
DovatoDolutegravir Sodium/Lamivudine104$300,954
JulucaDolutegravir/Rilpivirine80$276,695
RukobiaFostemsavir Tromethamine29$255,383
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf47$218,724
CabenuvaCabotegravir/Rilpivirine17$115,439
IsentressRaltegravir Potassium38$76,772
TriumeqAbacavir/Dolutegravir/Lamivudi15$55,089
GenvoyaElviteg/Cob/Emtri/Tenof Alafen11$42,917
TivicayDolutegravir Sodium16$35,458
Etravirine23$25,494
Maraviroc16$21,243
Fosfomycin Tromethamine58$9,604
Ritonavir12$3,757
Acyclovir28$453

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyDovato, Juluca, Rukobia, Cabenuva, Triumeq$19,560$1,039,018261 claims
GileadBiktarvy, Genvoya$2,345$401,90999 claims
Janssen Products, LPSymtuza$170$218,72447 claims
MerckIsentress$1,040$76,77238 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 669 infectious disease providers in Florida.

Other infectious disease in South Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →